Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adoptive cell therapies in thoracic malignancies: a comprehensive review.
Garitaonaindia Y, Martínez-Cutillas M, Uribarren M, Redondo I, Calvo V, Serna-Blasco R, Provencio M. Garitaonaindia Y, et al. Among authors: calvo v. Clin Transl Oncol. 2025 Jan 9. doi: 10.1007/s12094-024-03834-5. Online ahead of print. Clin Transl Oncol. 2025. PMID: 39789380 Review.
Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer.
Molina-Alejandre M, Perea F, Calvo V, Martinez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martinez-Martí A, Insa A, Massuti B, Viteri S, Barneto Aranda I, Rodriguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, Provencio M, Cruz-Bermúdez A. Molina-Alejandre M, et al. Among authors: calvo v. J Immunother Cancer. 2024 Oct 20;12(10):e009762. doi: 10.1136/jitc-2024-009762. J Immunother Cancer. 2024. PMID: 39428126 Free PMC article.
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.
Provencio M, Nadal E, Insa A, García Campelo R, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro J, Gómez de Antonio D, Macia I, Figueroa S, Fernández Vago L, Calvo V, Palmero R, Sierra-Rodero B, Martínez-Toledo C, Molina-Alejandre M, Serna-Blasco R, Romero A, Cruz-Bermúdez A. Provencio M, et al. Among authors: calvo v. Lancet Oncol. 2024 Nov;25(11):1453-1464. doi: 10.1016/S1470-2045(24)00498-4. Epub 2024 Oct 14. Lancet Oncol. 2024. PMID: 39419061 Free PMC article. Clinical Trial.
Quality of care assessment for non-small cell lung cancer patients: transforming routine care data into a continuous improvement system.
Sánchez JC, Nuñez-García B, Garitaonaindia Y, Calvo V, Blanco M, Ramos Martín-Vegue A, Royuela A, Manso M, Cantos B, Méndez M, Collazo-Lorduy A, Provencio M. Sánchez JC, et al. Among authors: calvo v. Clin Transl Oncol. 2024 Aug 16. doi: 10.1007/s12094-024-03658-3. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39147937
Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk.
Calvo V, Niazmand E, Carcereny E, Rodriguez-Abreu D, Cobo M, López-Castro R, Guirado M, Camps C, Laura Ortega A, Bernabé R, Massutí B, Garcia-Campelo R, Del Barco E, Luis González-Larriba J, Bosch-Barrera J, Martínez M, Torrente M, Vidal ME, Provencio M. Calvo V, et al. Lung Cancer. 2024 Sep;195:107920. doi: 10.1016/j.lungcan.2024.107920. Epub 2024 Aug 9. Lung Cancer. 2024. PMID: 39137596 Free article.
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
Provencio M, Robado de Lope L, Serna-Blasco R, Nadal E, Diz Tain P, Massuti B, González-Larriba JL, Insa A, Sánchez-Hernández A, Casal-Rubio J, García-Campelo R, Sequero López S, Rogado J, Martínez-Martí A, Bosch-Barrera J, Bernabé R, Vázquez Estévez S, Ponce S, de Castro J, Coves Sarto J, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Peña Cabia S, López Martín A, Sala González MÁ, Cobo M, Camps C, Barneto I, Calvo V, Collazo-Lorduy A, Cruz-Bermúdez A, Romero A. Provencio M, et al. Among authors: calvo v. Lung Cancer. 2024 Aug;194:107865. doi: 10.1016/j.lungcan.2024.107865. Epub 2024 Jun 26. Lung Cancer. 2024. PMID: 38945004 Free article.
Inhibition of the Eukaryotic Initiation Factor-2-α Kinase PERK Decreases Risk of Autoimmune Diabetes in Mice.
Muralidharan C, Huang F, Enriquez JR, Wang JE, Nelson JB, Nargis T, May SC, Chakraborty A, Figatner KT, Navitskaya S, Anderson CM, Calvo V, Surguladze D, Mulvihill MJ, Yi X, Sarkar S, Oakes SA, Webb-Robertson BM, Sims EK, Staschke KA, Eizirik DL, Nakayasu ES, Stokes ME, Tersey SA, Mirmira RG. Muralidharan C, et al. Among authors: calvo v. bioRxiv [Preprint]. 2024 Jun 3:2023.10.06.561126. doi: 10.1101/2023.10.06.561126. bioRxiv. 2024. Update in: J Clin Invest. 2024 Jun 18;134(16):e176136. doi: 10.1172/JCI176136 PMID: 38895427 Free PMC article. Updated. Preprint.
Inhibition of the eukaryotic initiation factor-2α kinase PERK decreases risk of autoimmune diabetes in mice.
Muralidharan C, Huang F, Enriquez JR, Wang JE, Nelson JB, Nargis T, May SC, Chakraborty A, Figatner KT, Navitskaya S, Anderson CM, Calvo V, Surguladze D, Mulvihill MJ, Yi X, Sarkar S, Oakes SA, Webb-Robertson BM, Sims EK, Staschke KA, Eizirik DL, Nakayasu ES, Stokes ME, Tersey SA, Mirmira RG. Muralidharan C, et al. Among authors: calvo v. J Clin Invest. 2024 Jun 18;134(16):e176136. doi: 10.1172/JCI176136. J Clin Invest. 2024. PMID: 38889047 Free PMC article.
254 results